Ignite Creation Date:
2024-05-06 @ 3:21 PM
Last Modification Date:
2024-10-26 @ 1:48 PM
Study NCT ID:
NCT04608318
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-06
First Post:
2020-10-23
Brief Title:
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia CLL
Sponsor:
German CLL Study Group
Organization:
German CLL Study Group
Organization Data
Organization:
German CLL Study Group
Class:
OTHER
Study ID:
CLL17
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
German CLL Study Group
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| The Israeli CLL Study Group ICLLSG | UNKNOWN |
| Stichting Hemato-Oncologie voor Volwassenen Nederland HOVON | UNKNOWN |
| Nordic CLL Study Group NCLLSG | UNKNOWN |
| Swiss Group for Clinical Cancer Research SAKK | UNKNOWN |
| Cancer Trials Ireland | NETWORK |
| Gruppo Italiano Malattie EMatologiche dellAdulto GIMEMA | UNKNOWN |
| Grupo Español de Leucemia Linfocítica Crónica GELLC | UNKNOWN |